Palatin Technologies Inc

Palatin Technologies Inc a biopharmaceutical company develops targeted receptorspecific therapeutics for the treatment of various diseases in the United States The companys lead product is Vyleesi a melanocortin receptor MCr agonist for the treatment of premenopausal women with hypoactive sexual desire disorder It is also developing oral PL8177 a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases In addition the company engages in the development of PL9643 a peptide melanocortin agonist active at multiple MCrs including MC1r and MC5r for antiinflammatory ocular indications such as dry eye disease and melanocortin peptides for diabetic retinopathy Further it is developing PL3994 a natriuretic peptide receptor NPRA agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications and PL5028 an NPRA and NPRbinder to treat cardiovascular and fibrotic diseases including reducing cardiac hypertrophy and fibrosis The company was incorporated in 1986 and is based in Cranbury New Jersey